Characteristics of the 25 non-Hodgkin and Hodgkin lymphomas associated with low-dose methotrexate in RA patients
| Patient . | Sex . | Age . | Lymphoma classification . | Extranodal location . | EBV . | Clonality . | Duration of RA (y) . | Duration of MTX (mo) . | Total dose of MTX (mg) . | Secondary Sjögren . | Associated CS or IS drugs . | Previous DMARD . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 75 | NHL T pleomorphic | − | − | UN | 6 | 24 | 1325 | − | CS | 0 |
| 2 | F | 67 | NHL large B cell | − | + | + | 10 | 63 | 3260 | − | Aza + CS | 3 |
| 3 | F | 71 | NHL large B cell | − | − | − | 22 | 120 | 5200 | − | CS | 4 |
| 4 | F | 74 | NHL MZ B cell | Stomach | − | UN | 27 | 84 | 2730 | − | CS | 1 |
| 5 | M | 67 | NHL large B cell | − | − | + | 15 | 144 | 4560 | + | CS | 3 |
| 6 | F | 64 | NHL large B cell | Bone | − | + | 10.5 | 69 | 3085 | − | CS | 6 |
| 7 | F | 44 | NHL large B cell | Orbit | − | UN | 8 | 63 | 2000 | − | HCQ | 1 |
| 8 | F | 70 | NHL large B cell | Stomach | + | UN | 29 | 31 | 1500 | − | Cyclo + CS | 5 |
| 9 | M | 58 | NHL T LGL | Bone marrow | + | + | 2.5 | 6 | 300 | + | CS | 1 |
| 10 | F | 51 | NHL large B cell | Pleura | − | + | 7 | 40 | 1700 | − | − | 0 |
| 11 | F | 73 | NHL MZ B cell | Lung | − | + | 49 | 16 | 865 | − | CS | 2 |
| 12 | M | 67 | NHL large B cell | − | − | UN | 25 | 84 | 2000 | − | − | 3 |
| 13 | F | 69 | NHL large B cell | Skin | − | + | 22 | 156 | 5100 | − | CS | 6 |
| 14 | M | 68 | NHL B lymphocytic | − | − | + | 7 | 21 | 944 | − | CS | 6 |
| 15 | F | 66 | NHL MZ B cell | Skin Orbit | − | + | 3.9 | 16 | 517 | − | CS | 1 |
| 16 | F | 69 | NHL large B cell | Bone | − | UN | 21 | 60 | 1630 | − | CS | 2 |
| 17 | F | 64 | NHL large B cell | Lung | − | + | 24 | 69 | 2250 | − | − | 2 |
| 18 | M | 52 | NHL large B cell | Thyroid | − | UN | 11 | 96 | 4800 | − | CS | 2 |
| 19 | M | 65 | HD (II, type 2) | − | − | 16 | 60 | 2600 | − | − | 3 | |
| 20 | M | 55 | HD (III, type 3) | − | − | 24 | 72 | 4600 | − | CS | 3 | |
| 21 | M | 46 | HD (III, type 3) | − | + | 12 | 42 | 1900 | − | CS | 2 | |
| 22 | F | 82 | HD (III, type 3) | − | + | 11 | 40 | 1115 | − | CS | 2 | |
| 23 | F | 55 | HD (III, type 2) | − | + | 29 | 72 | 2500 | − | CS | 4 | |
| 24 | M | 39 | HD (III, type 3) | − | + | 5 | 16 | 585 | − | Tiop | 2 | |
| 25 | M | 43 | HD (IV) | Liver | + | 10 | 38 | 1800 | − | CS | 3 |
| Patient . | Sex . | Age . | Lymphoma classification . | Extranodal location . | EBV . | Clonality . | Duration of RA (y) . | Duration of MTX (mo) . | Total dose of MTX (mg) . | Secondary Sjögren . | Associated CS or IS drugs . | Previous DMARD . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 75 | NHL T pleomorphic | − | − | UN | 6 | 24 | 1325 | − | CS | 0 |
| 2 | F | 67 | NHL large B cell | − | + | + | 10 | 63 | 3260 | − | Aza + CS | 3 |
| 3 | F | 71 | NHL large B cell | − | − | − | 22 | 120 | 5200 | − | CS | 4 |
| 4 | F | 74 | NHL MZ B cell | Stomach | − | UN | 27 | 84 | 2730 | − | CS | 1 |
| 5 | M | 67 | NHL large B cell | − | − | + | 15 | 144 | 4560 | + | CS | 3 |
| 6 | F | 64 | NHL large B cell | Bone | − | + | 10.5 | 69 | 3085 | − | CS | 6 |
| 7 | F | 44 | NHL large B cell | Orbit | − | UN | 8 | 63 | 2000 | − | HCQ | 1 |
| 8 | F | 70 | NHL large B cell | Stomach | + | UN | 29 | 31 | 1500 | − | Cyclo + CS | 5 |
| 9 | M | 58 | NHL T LGL | Bone marrow | + | + | 2.5 | 6 | 300 | + | CS | 1 |
| 10 | F | 51 | NHL large B cell | Pleura | − | + | 7 | 40 | 1700 | − | − | 0 |
| 11 | F | 73 | NHL MZ B cell | Lung | − | + | 49 | 16 | 865 | − | CS | 2 |
| 12 | M | 67 | NHL large B cell | − | − | UN | 25 | 84 | 2000 | − | − | 3 |
| 13 | F | 69 | NHL large B cell | Skin | − | + | 22 | 156 | 5100 | − | CS | 6 |
| 14 | M | 68 | NHL B lymphocytic | − | − | + | 7 | 21 | 944 | − | CS | 6 |
| 15 | F | 66 | NHL MZ B cell | Skin Orbit | − | + | 3.9 | 16 | 517 | − | CS | 1 |
| 16 | F | 69 | NHL large B cell | Bone | − | UN | 21 | 60 | 1630 | − | CS | 2 |
| 17 | F | 64 | NHL large B cell | Lung | − | + | 24 | 69 | 2250 | − | − | 2 |
| 18 | M | 52 | NHL large B cell | Thyroid | − | UN | 11 | 96 | 4800 | − | CS | 2 |
| 19 | M | 65 | HD (II, type 2) | − | − | 16 | 60 | 2600 | − | − | 3 | |
| 20 | M | 55 | HD (III, type 3) | − | − | 24 | 72 | 4600 | − | CS | 3 | |
| 21 | M | 46 | HD (III, type 3) | − | + | 12 | 42 | 1900 | − | CS | 2 | |
| 22 | F | 82 | HD (III, type 3) | − | + | 11 | 40 | 1115 | − | CS | 2 | |
| 23 | F | 55 | HD (III, type 2) | − | + | 29 | 72 | 2500 | − | CS | 4 | |
| 24 | M | 39 | HD (III, type 3) | − | + | 5 | 16 | 585 | − | Tiop | 2 | |
| 25 | M | 43 | HD (IV) | Liver | + | 10 | 38 | 1800 | − | CS | 3 |
CS indicates corticosteroids; IS, immunosuppressive drugs; +, present; −, absent; UN, unknown; Aza, azathioprine; HCQ, hydroxychloroquine; Cyclo, cyclosporine; Tiop, tiopronine.